air for living

Respiratory diseases literally take the air to breathe away from patients and are often associated with considerable psychological strain. This is also the case with asthma, a chronic inflammatory respiratory disease with paroxysmal dyspnoea. Therapy for this condition combines long-term medication with quick-relief medication. It is our objective to enable patients to live "trouble-free" as far as possible. Specifically with regard to a possible life-long, long-term medication, it is vital to continue to optimise existing therapy approaches.

This is the challenge we set ourselves and our most recent success has been in the development of a product combining two active ingredients that have proved their worth individually over a long period in the therapy of respiratory diseases. It contains the long-acting beta-agonist formoterol and the inhaled corticosteroid fluticasone.

This product combines the two active ingredients in a pressurised metered dose inhaler (pMDI) and will be used for the regular treatment of asthma. We expect this combination to significantly improve the therapy options for patients through the inflammation-inhibiting effect, the proven asthma control of fluticasone as well as the long-lasting bronchodilation effect of formoterol.

In addition to this we are working on the development of respiratory products to be delivered via a novel breath-actuated pMDI known as the K-HalerĀ® which we are confident will become the device of choice amongst patients and physicians for the future.




print page